IngridMayerMDMSCI

Summary

• Since I became a breast cancer clinical researcher, my mission and goal have always been to mitigate breast cancer, which still remains the most common cancer in women in the world. After 20 years in academia and clinical practice, my current role at AstraZeneca allows me to impact breast cancer care in a much larger scale, to promote paradigm-shifting and practice-changing treatments to decrease breast cancer mortality, morbidity, and health disparities in a way that is responsive to patients’ needs and addresses the most important knowledge gaps in the breast cancer medical field. My overarching vision is to pioneer and expand novel translational global research and innovative clinical trial development that accelerate the approval of established and novel drugs in the key areas of excellence at AstraZeneca: tumor resistance/ targeted therapies, DNA damage response, antibody-drug conjugates, and immune-oncology.
  Prior to joining AstraZeneca, I was a Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center (VUMC)/ Vanderbilt-Ingram Cancer Center (VICC) for 18 years, and a breast medical oncologist by training. My translational research endeavors were focused on the identification of targetable pathways in breast cancer and mechanisms of resistance to breast cancer therapies, and have been funded by the NCI, SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation. I have been PI on more than 90 clinical trials, with more than 20 investigator-initiated trials (IITs). I also have had a successful track record of mentoring fellows and junior faculty throughout my career. Nationally, aside from having been an active member of the ECOG-ACRIN Breast Core Committee and the VICC representative of the National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, I was highly involved with the Translational Breast Cancer Research Consortium (TBCRC).